Investment Rating - The report maintains a "Buy" rating for the company [2] Core Insights - The company is transitioning from a high-end offline maternity service provider to a comprehensive maternal and infant health service platform driven by AI technology [4][5] - The "Bela Doctor" app serves as the core entry point for a full-cycle service ecosystem, integrating external AI capabilities and internal professional service systems [6] - The company has established a scientific "age-based parenting" service system, enhancing customer experience and brand loyalty [7] - Strategic investment in AI service provider WITH1000 AI aims to improve user understanding and industry standards [8] - Collaboration with China Merchants Bank to create a secure maternity guarantee fund account enhances customer confidence [9] Financial Projections - Revenue forecasts for 2025-2027 are projected at 1.076 billion, 1.403 billion, and 1.777 billion yuan, representing year-on-year growth of 34.73%, 30.42%, and 26.65% respectively [11] - Net profit forecasts for the same period are 315 million, 406 million, and 478 million yuan, with growth rates of 157.65%, 28.75%, and 17.71% respectively [11] - The company is expected to achieve an EPS of 0.51, 0.65, and 0.77 yuan for 2025, 2026, and 2027 [13]

证券研究报告：食品饮料 | 公司点评报告 发布时间：2026-01-29 研究所 分析师:蔡雪昱 SAC 登记编号:S1340522070001 Email:caixueyu@cnpsec.com 分析师:杨逸文 SAC 登记编号:S1340522120002 Email:yangyiwen@cnpsec.com 圣贝拉 (2508.HK) 以 AI+服务为核心，全面升级母婴护理生态 ⚫ 事件 公司近期围绕"家庭大健康生态战略"进行一系列系统化、多维度 的能力升级，从一家高端线下月子服务商，加速向一个以 AI 技术为 引擎、专业体系为基石、金融级信任为护城河的母婴健康综合服务平 台演进。 股票投资评级 买入|维持 公司基本情况 | 最新收盘价（港元） | 4.69 | | --- | --- | | 总股本/流通股本（亿股）6.22 / 6.22 | | | 总市值/流通市值（亿港 | 29.37/ 29.37 | | 元） | | | 52 周内最高/最低价 | 11.00/3.40 | | 资产负债率(%) | 36.35% | | 市盈率 | -5.04 | | 第一大股东 | 向华 | ⚫ 投资要点 ...

公司基本情况 | 最新收盘价（元） | 199.89 | | --- | --- | | 总股本/流通股本（亿股）4.80 | / 4.36 | | 总市值/流通市值（亿元）960 | / 872 | | 52 周内最高/最低价 | 212.45 / 92.60 | | 资产负债率(%) | 36.8% | | 市盈率 | 75.72 | | 第一大股东 | ACM RESEARCH, | | INC. | | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 盛美上海(688082) 证券研究报告：电子 | 公司点评报告 股票投资评级 指引强劲增长 l 投资要点 产品平台化持续推进，2026 年营收指引高增。截至 2025 年 9 月 29 日，公司在手订单总金额为 90.72 亿元，与上年同期已自愿 性披露的在手订单数据相比，在手订单总金额同比增加 34.10%。 公司销售交货及调试验收工作持续高效推进，有效保障了经 ...

| 最新收盘价（元） | 199.89 | | --- | --- | | 总股本/流通股本（亿股）4.80 | / 4.36 | | 总市值/流通市值（亿元）960 | / 872 | | 52 周内最高/最低价 | 212.45 / 92.60 | | 资产负债率(%) | 36.8% | | 市盈率 | 75.72 | | 第一大股东 | ACM RESEARCH, | | INC. | | 研究所 证券研究报告：电子 | 公司点评报告 股票投资评级 公司基本情况 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 盛美上海(688082) 指引强劲增长 l 投资要点 产品平台化持续推进，2026 年营收指引高增。截至 2025 年 9 月 29 日，公司在手订单总金额为 90.72 亿元，与上年同期已自愿 性披露的在手订单数据相比，在手订单总金额同比增加 34.10%。 公司销售交货及调试验收工作持续高效推进，有效保障了经 ...

证券研究报告：宏观报告 发布时间：2026-01-28 研究所 分析师:袁野 SAC 登记编号:S1340523010002 Email:yuanye@cnpsec.com 研究助理:苑西恒 SAC 登记编号:S1340124020005 Email:yuanxiheng@cnpsec.com 近期研究报告 《高频数据显示生产和外需平稳，投 资增速改善仍需观察》 - 2026.01.26 宏观研究 2025 年工业利润迎正增长，高技术制造领跑显结 构活力 核心观点 市场有风险，投资需谨慎 请务必阅读正文之后的免责条款部分 目 录 | 1 2025年工业企业利润增速转正,12月当月增速改善明显 | | --- | | 2 营运能力改善与资产负债率回落，企业信心仍有待改善 | | 3 高技术制造业领跑工业盈利 . | | 风险提示 . | 请务必阅读正文之后的免责条款部分 2025 年全国规模以上工业企业实现利润总额同比增速为 0.6%， 近三年首次由负转正，企业盈利逐步修复；从年内来看，1-12 月利润 总额同比增速边际改善较为明显，较前值提升 0.5 个百分点，且不存 在低基数影响；从当月来看，12月工业企业 ...

证券研究报告：商贸零售|点评报告 行业投资评级 强于大市|维持 近期研究报告 《11 月社零数据如何？》 - 2025.12.22 12 月社零数据如何？ ⚫ 事件 | 行业基本情况 | | --- | | 收盘点位 | | 2470.34 | | --- | --- | --- | | 52 | 周最高 | 2584.65 | | 52 | 周最低 | 1877.67 | 行业相对指数表现（相对值） -8% -5% -2% 1% 4% 7% 10% 13% 16% 19% 22% 25% 2025-02 2025-04 2025-06 2025-09 2025-11 2026-01 商贸零售 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:李鑫鑫 SAC 登记编号:S1340525010006 Email:lixinxin@cnpsec.com 国家统计局发布最新社零数据，12 月份，社会消费品零售总额 45136 亿元，同比增长 0.9%。其中，除汽车以外的消费品零售额 39654 亿元，增长 1.7%。2025 年，社会消费品零售总额 501202 亿元，比上 年增长 3.7%。其中，除汽车 ...

Industry Investment Rating - The industry investment rating is maintained at "Outperform" [2] Core Insights - The basic chemical industry index closed at 4971.22 points, up 7.29% from the previous week, outperforming the CSI 300 index by 7.91% [16][19] - Among 24 sub-industries, 23 saw price increases, with the leading sectors being other chemical raw materials, textile chemical products, chlor-alkali, coal chemical, and viscose, with weekly increases of 12.94%, 12.92%, 10.93%, 10.50%, and 10.21% respectively [19][21] - The report highlights China's commitment to implementing a dual control system for carbon emissions, aiming for peak carbon emissions before 2030 and carbon neutrality by 2060 [6] Weekly Chemical Market Overview - The basic chemical industry index rose to 4971.22 points, marking a 7.29% increase compared to the previous week, and outperformed the CSI 300 index by 7.91% [16][19] - The report tracked 380 chemical products, with 114 showing price increases and 54 showing decreases [23] - The top ten products with the highest price increases included solid methionine, NYMEX natural gas, and battery-grade lithium carbonate, with increases ranging from 7% to 128% [25] Key Chemical Sub-Industry Tracking Polyester Filament Yarn - The market price for polyester filament yarn increased, with POY averaging 6710 CNY/ton, FDY at 6950 CNY/ton, and DTY at 7850 CNY/ton [27] - The average industry operating rate for polyester filament yarn was approximately 85.27% [28] - The average processing margin for POY was 1189.33 CNY/ton, indicating a profit increase compared to the previous week [29][30] Tire Industry - The operating rate for the all-steel tire industry was 62.53%, while the semi-steel tire industry saw an increase to 73.84% [41] - The average price of styrene-butadiene rubber decreased by 1.53% to 12096.25 CNY/ton [43] - The report noted a decline in export volumes for major tire companies in Southeast Asia [41][42] Refrigerants - The domestic refrigerant R22 market remained stable, with prices holding steady compared to the previous week [49] - Mainstream companies quoted R22 at 15500-18000 CNY/ton, with no significant willingness to lower prices [50]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company is entering a new drug approval harvest period with a well-structured pipeline covering ADC (Antibody-Drug Conjugates) and IO (Immuno-Oncology) [3][10]. - The company has multiple oncology product pipelines, including immune therapy, ADC targeted therapy, and oncolytic virus drugs, with several candidates in clinical stages [3][11]. - The company achieved its first profitability and positive operating cash flow in the first half of 2025, driven by business development and sales [3][25]. Summary by Sections R&D Coverage and Pipeline - The company focuses on oncology treatment, establishing a comprehensive ADC technology platform and has developed multiple ADC products, including PD-1 monoclonal antibody and MRG003 [11][14]. - The pipeline includes six ADC drugs, one oncolytic virus, and one TCE (T-cell Engager) drug in clinical stages, with several candidates entering pivotal trials [14][18]. Unique Features of ADC Candidates - MRG003 (EGFR ADC) has been approved for NPC (Nasopharyngeal Carcinoma) in China, showing superior survival benefits and safety compared to competitors [4][30]. - MRG004A (TF-ADC) is in Phase III trials for pancreatic cancer, while MRG006A (GPC3 ADC) targets the liver cancer market and is expected to enter Phase III trials in 2026 [6][30]. Oncolytic Virus and International Expansion - The company introduced the oncolytic virus therapy CG0070, which is in critical registration trials in China and has shown promising efficacy in the U.S. for bladder cancer [5][30]. - The company has successfully partnered for international expansion with MRG007 (CDH17 ADC) and CTM012 (CD3/4-1BB/DLL3 tri-antibody) [5][30]. Financial Projections and Investment Recommendations - Revenue projections for 2025, 2026, and 2027 are estimated at 880 million, 1.02 billion, and 1.49 billion yuan, respectively, with expected growth rates of 138%, 16%, and 47% [6][30]. - The company is still in the investment phase for innovative drug development, with projected net profits of -20 million, 10 million, and 280 million yuan for the same years [6][30].

Investment Rating - The report maintains a "Buy" rating for the company [2][7] Core Insights - The company is expected to achieve revenue of 4.2 to 4.6 billion yuan in 2025, representing a year-on-year increase of 16.37% to 27.45%, with a net profit attributable to the parent company of 75 to 100 million yuan, an increase of 13.08% to 50.77% [5] - The global semiconductor industry continues to grow, driven by demand in artificial intelligence, high-performance computing, and data center infrastructure [5] - The company is enhancing its advanced packaging capabilities, which are expected to improve delivery times and quality control for clients [5] - The company plans to invest up to 2.1 billion yuan in a new integrated circuit packaging and testing production base in Malaysia to deepen cooperation with overseas clients [6] Financial Projections - Revenue projections for 2025, 2026, and 2027 are 4.4 billion, 5.5 billion, and 7 billion yuan respectively, with net profits of 90.53 million, 273.14 million, and 453.60 million yuan [10][11] - The company anticipates a revenue growth rate of 22.68% in 2025 and 24.51% in 2026 [11] - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 0.22 yuan, 0.67 yuan, and 1.11 yuan respectively [10][11]

证券研究报告：宏观报告 研究所 分析师:李起 SAC 登记编号:S1340524110001 Email:liqi2@cnpsec.com 研究助理:高晓洁 SAC 登记编号:S1340124020001 Email:gaoxiaojie@cnpsec.com 近期研究报告 《高频数据显示生产和外需平稳，投资 增速改善仍需观察》 - 2026.01.26 宏观观点 海外宏观周报：美联储降息将按下暂停键 ⚫ 核心观点： 上周达沃斯论坛释放的信号强化了投资者对全球增长不确定性 与风险溢价上行的定价，黄金价格显著走高，反映出宏观与地缘因素 仍是当前资产配置的重要约束。预计欧洲的国防及战略自主能力将逐 步增强。 货币政策方面，在去年下半年连续三次风险管理式降息后，本周 美联储议息会议或将迎来首次暂停。在即将到来的会议上，鲍威尔主 席可能会强调，FOMC 刚刚进行了三次降息，对当前的货币政策立场感 到满意，并不急于进一步调整利率。预计鲍威尔会重申货币政策将依 赖后续的数据灵活决策，同时表示现行利率水平仅具有轻微的紧缩效 果。重点应关注鲍威尔对美国就业形势的判断。往后看，我们认为， 美国当前呈现的 K 型经济结构并不支持 ...